Erratum

Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ [Eur J Cancer 108 (February 2019) 33—40]

Marie Auvray a, Edouard Auclin b,c,d, Philippe Barthelemy e, Petri Bono f, Pirkko Kellokumpu-Lehtinen g, Marine Gross-Goupil h, Guillermo De Velasco i, Thomas Powles j, Guillaume Mouillet k, Yann-Alexandre Vano l, Gwenaelle Gravis m, Loic Mourey n, Franck Priou o, Frederic Rolland p, Bernard Escudier a, Laurence Albiges a,∗

Medical Oncology, Gustave Roussy, Universite Paris-Saclay, Villejuif, France
Gastrointestinal Oncology Department, European Georges Pompidou Hospital, Universite Rene Descartes, Paris, France
Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, France
Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France
Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
Department of Oncology, Tampere University Hospital and University of Tampere, Tampere, Finland
Oncology Department, Centre Hospitalier Universitaire, Bordeaux, Aquitaine, France
Department of Medical Oncology, University Hospital 12 de Octubre, I + 12, Madrid, Spain
Barts Cancer Institute, Queen Mary University of London, London, UK
Department of Medical Oncology, University Hospital, Besançon, France
Oncology Department, European Georges Pompidou Hospital, Université René Descartes, Paris, France
Medical Oncology, Institut Paoli-Calmettes, Marseille, France
Department of Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France
Department of Oncology, Centre Hospitalier Departemental Les Oudairies, La Roche-sur-Yon, France
Medical Oncology, Institut René Gauducheau, Saint Herblain, France

The publisher regrets the conflict of interest information provided by the authors was not included in the paper and instead the incorrect statement ‘None declared’ was published. The publisher would like to apologise for any inconvenience caused.

DOI of original article: https://doi.org/10.1016/j.ejca.2018.11.031.
* Corresponding author: Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Fax: +33142115305.
E-mail address: laurence.albiges@gustaveroussy.fr (L. Albiges).

Please see below the statement provided by the authors:

G.D.V. declared consultancy or advisory role for Janssen, Pfizer, Novartis, Bayer and Astellas—Medivation and funding from Ipsen. P.Ba. declared consultancy or advisory role for Pfizer, Novartis, Ipsen, Bristol-Myers Squibb (BMS), Roche, Merck, and Janssen. G.M. declared consultancy or advisory role for Pfizer, Novartis, Ipsen, BMS and Janssen. Y.-A.V. declared receiving honoraria and consulting or advisory role for Pfizer, Novartis, BMS,